Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions

Summary

Global coagulation assays display variable effects at different concentrations of rivaroxaban. The aim of this study is to quantify the ex vivo effects of low-dose rivaroxaban on thrombophilia screening assays and coagulation factor activities based on the administration time, and to show how to mask possible interferences. Plasma samples from 40 patients receiving rivaroxaban 10 mg daily were investigated to measure activities of clotting factor II, V, VII, VIII, IX, XI, XII and XIII; protein C- and protein S-levels; lupus anticoagulants; anticardiolipin IgG and IgM; D-dimer, heparin-platelet factor 4 (HPF4) antibodies and screening tests for von Willebrand disease (VWD). Two hours after rivaroxaban administration, the activities of clotting factors were significantly decreased to different extents, except for factor XIII. Dilution of plasma samples resulted in neutralisation of these interferences. The chromogenic protein C activity assay was not affected by rivaroxaban. Depending on the timing of tablet intake in relation to blood sampling protein S activity was measured falsely high when a clotting assay was used. False-positive results for lupus anticoagulants were observed depending on the assay system used and the administration time of rivaroxaban. ELISA-based assays such as anticardiolipin IgG and IgM, D-dimer, HPF4-antibodies and the turbidimetric assays for VWD were not affected by rivaroxaban. Specific haemostasis clotting tests should be performed directly prior to rivaroxaban intake. Assay optimisation in the presence of rivaroxaban can be achieved by plasma dilution. Immunologic assays are not influenced by rivaroxaban, while chromogenic assays can be used, when they do not depend on factor Xa.

Keywords

Clotting factor activity - D-dimer - lupus anticoagulants - protein C - protein S - rivaroxaban - von Willebrand disease

• References

• 1 Kubitza D, Becka M, Voith B. et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421. DOI:10.1016/j.clpt.2005.06.011.
• 2 Mueck W, Eriksson BI, Bauer KA. et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216. DOI:10.2165/00003088-200847030-00006.
• 3 Perzborn E, Strassburger J, Wilmen A. et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 03: 514-521. DOI:10.1111/j.1538-7836.2005.01166.x.
• 4 Samama MM, Martinoli JL, LeFlem L. et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 31 (103) 815-825.
• 5 Hillarp A, Baghaei F, Fagerberg Blixter I. et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 09: 133-139. DOI:10.1111/j.1538-7836.2010.04098.x.
• 6 Barrett YC, Wang Z, Frost C. et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271. DOI:10.1160/TH10-05-0328.
• 7 Mani H, Hesse C, Stratmann G. et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011; 106: 156-164. DOI:10.1160/TH10-10-0667.
• 8 Asmis LM, Alberio L, Angelillo-Scherrer A. et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories. Thromb Res 2012; 129: 492-498. DOI:10.1016/j.thromres.2011.06.031.
• 9 Gerotziafas GT, Baccouche H, Sassi M. et al. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res 2012; 129: 101-103. DOI:10.1016/j.thromres.2011.09.004.
• 10 Tichelaar V, de Jong H, Nijland H. et al. Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays. Thromb Haemost 2011; 106: 990-992. DOI:10.1160/TH11-04-0277.
• 11 Merriman E, Kaplan Z, Butler J. et al. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 2011; 105: 385-386. DOI:10.1160/TH10-08-0511.
• 12 Rohde G. Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor- in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872: 43-50. DOI:10.1016/j.jchromb.2008.07.015.
• 13 Pengo V, Tripodi A, Reber G. et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis . Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis . J Thromb Haemost 2009; 07: 1737-1740. DOI:10.1111/j.1538-7836.2009.03555.x.
• 14 Lindhoff-Last E, Humpich M, Schmitt J. et al. MIXCON -LA: a precise, sensitive and specific aPTT-based assay for detection of lupus anticoagulant. Clin Appl Thromb Hemost 2002; 08: 163-167. DOI:10.1177/107602960200800213.
• 15 Os GMA, de Laat B, Kamphuisen PW. et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 2011; 09: 1657-1659. DOI:10.1111/j.1538-7836.2011.04395.x.
• 16 Jacobsen EM, Barna-Cler L, Taylor JM. et al. The lupus ratio test an interlaboratory study on the detection of lupus anticoagulants by an APTT-based, integrated and semi-quantitative test. Thromb Haemost 2000; 83: 704-708.
• 17 Esmon NL, Safa O, Smirnov MD. et al. Antiphospholipid antibodies and the protein C pathway. J Autoimmun 2000; 15: 221-225. DOI:10.1006/jaut.2000.0407.
• 18 Mueck W, Lensing AW, Agnelli G. et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-686. DOI:10.2165/11595320-000000000-00000.